Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by Rathbones Group PLC

Rathbones Group PLC boosted its stake in Guardant Health, Inc. (NASDAQ:GH) by 6.6% during the 4th quarter, HoldingsChannel reports. The fund owned 198,961 shares of the company’s stock after buying an additional 12,375 shares during the period. Rathbones Group PLC’s holdings in Guardant Health were worth $6,078,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new stake in Guardant Health during the fourth quarter worth about $26,000. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the 4th quarter valued at approximately $43,000. Kimelman & Baird LLC bought a new position in Guardant Health during the 4th quarter worth $58,000. Quantbot Technologies LP acquired a new stake in Guardant Health in the fourth quarter worth $80,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after acquiring an additional 817 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Guggenheim restated a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Stephens restated an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a research report on Wednesday, March 26th. Raymond James reiterated an “outperform” rating and set a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, Barclays started coverage on shares of Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective for the company. Twenty equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $48.95.

Guardant Health Trading Up 3.0 %

GH opened at $41.78 on Tuesday. The stock has a fifty day moving average price of $44.28 and a 200 day moving average price of $35.07. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of -11.74 and a beta of 1.45.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.